Health Care & Life Sciences » Biotechnology | Applied Genetic Technologies Corp.

Applied Genetic Technologies Corp. | Balance Sheet

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
22,893.00
73,073.00
61,641.00
98,532.00
126,700.00
104,905
Total Accounts Receivable
143.00
487.00
883.00
954.00
174.00
210
Other Current Assets
475.00
1,876.00
1,608.00
3,089.00
3,361.00
4,009
Total Current Assets
23,511.00
75,436.00
64,132.00
102,575.00
130,235.00
109,124
Net Property, Plant & Equipment
341.00
402.00
478.00
2,627.00
2,661.00
5,254
Total Investments and Advances
-
-
23,629.00
74,183.00
13,749.00
1,980
Long-Term Note Receivable
-
-
480.00
-
-
-
Intangible Assets
1,630.00
1,565.00
1,448.00
1,321.00
1,219.00
968
Other Assets
8.00
4.00
7.00
91.00
59.00
1,206
Total Assets
25,490.00
77,407.00
90,174.00
180,797.00
147,923.00
118,532
ST Debt & Current Portion LT Debt
2,097.00
-
-
-
-
Accounts Payable
792.00
949.00
1,191.00
1,331.00
998.00
Income Tax Payable
-
-
-
-
1,514.00
Other Current Liabilities
571.00
1,585.00
3,451.00
53,412.00
25,644.00
Total Current Liabilities
3,460.00
2,534.00
4,642.00
54,743.00
28,156.00
Long-Term Debt
110.00
-
-
-
-
Other Liabilities
-
-
-
16,766.00
4,438.00
Total Liabilities
3,570.00
2,534.00
4,642.00
71,509.00
32,594.00
Common Equity (Total)
36,183.00
74,873.00
85,532.00
109,288.00
115,329.00
Total Shareholders' Equity
21,920.00
74,873.00
85,532.00
109,288.00
115,329.00
Total Equity
21,920.00
74,873.00
85,532.00
109,288.00
115,329.00
Liabilities & Shareholders' Equity
25,490.00
77,407.00
90,174.00
180,797.00
147,923.00
Preferred Stock (Carrying Value)
58,103.00
-
-
-
-

About Applied Genetic Technologies

View Profile
Address
14193 NW
Alachua Florida 32615
United States
Employees -
Website http://www.agtc.com
Updated 07/08/2019
Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology. Its product candidates are designed to treat X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W.